Semaglutide vs. tirzepatide: what 30-second TikToks get wrong

What's this video probably claiming?

Based on the caption and hashtag context, this video almost certainly walks viewers through what the creator frames as the "real" distinction between semaglutide and tirzepatide, likely hitting the talking points that dominate GLP-1 content right now: tirzepatide targets two receptors (GLP-1 and GIP) while semaglutide targets one, and that dual action translates to more weight loss. The creator probably positions tirzepatide as the stronger or "better" drug, possibly with language around it being the upgrade. Given the 30-second format, nuance is almost certainly sacrificed for punchy takeaways. The hashtag mix, pulling from both general wellness and specific medication journey tags, suggests this is aimed at people already considering or using these medications, not a clinical audience. That audience framing matters because viewers may be making real treatment decisions based on what gets said here.

What does the science actually show?

The mechanistic difference is real. Semaglutide is a GLP-1 receptor agonist approved at 2.4 mg weekly for weight management (Wegovy) and 0.5 to 2 mg for type 2 diabetes (Ozempic). Tirzepatide is a dual GIP and GLP-1 receptor agonist approved at doses up to 15 mg weekly (Zepbound, Mounjaro). The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15 mg produced mean weight loss of approximately 20.9% over 72 weeks in adults with obesity. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4 mg produced approximately 14.9% mean weight loss over 68 weeks. A head-to-head study, SURMOUNT-5 (results reported 2025), confirmed tirzepatide produced greater weight reduction on average. But averages mask real individual variation, and calling one drug universally better oversimplifies what clinicians actually see in practice.

Where does the social media noise diverge from clinical reality?

The main place TikTok content like this goes sideways is in flattening individual response variation into a simple hierarchy. Yes, tirzepatide shows greater average weight loss in trials, but trial populations and real-world patients are not the same group. Side effect profiles also differ in ways that matter clinically. Both drugs carry risks of nausea, vomiting, gastroparesis, and rare but serious pancreatitis concerns. The GIP component in tirzepatide may influence tolerability differently for some patients, though the evidence here is still developing. Short-form content also tends to ignore that access, cost, and contraindications drive prescribing decisions as much as efficacy data does. Compounded versions of both drugs have flooded the market, and creators rarely address that compounded formulations are not FDA-approved and should not be treated as equivalent to brand-name drugs. That omission is not a minor footnote.

What should you actually know?

If you are weighing these medications, the comparison that matters is not which drug wins on a TikTok scorecard. It is which drug fits your medical history, your risk profile, and your access situation. Both semaglutide and tirzepatide require a prescriber who reviews your full history, not a 30-second video. The SURMOUNT and STEP trial data are real, and the weight loss differences between drugs are clinically meaningful, but roughly one-third of patients in tirzepatide trials did not reach 15% weight loss either. Response is genuinely variable. Anyone presenting either medication as a guaranteed outcome or framing the choice as obvious is working from a marketing mindset, not a clinical one. Telehealth platforms that prescribe these medications are required to conduct proper intake evaluations. If a platform is not doing that, the drug comparison is the least of your concerns.